Moleculin Biotech Overview
Latest PEG ratio for Moleculin Biotech: -0.01 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-0.01
The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.
The latest PEG ratio for MBRX is -0.01. That is below the Healthcare sector average of 1.26. Investors often review this figure alongside Moleculin Biotech's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, MBRX currently prints -0.01 for PEG ratio, while the sector average sits near 1.26. That is roughly 101.2% below the sector mean. Large gaps often invite a closer look at Moleculin Biotech's growth, margins, and balance sheet.
A PEG ratio of -0.01 for Moleculin Biotech is not 'good' or 'bad' on its own. Compare it with the peer average (1.26) and with MBRX's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting MBRX's PEG ratio (-0.01), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Moleculin Biotech's PEG ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
